Edwards Reports Q2 Sales Climb 14% to $1.74B
Edwards Lifesciences (NYSE: EW) reported Q2 revenue of $1.74B, up 14% year over year, and adjusted EPS of 78 cents, above expectations. Full-year sales guidance was raised to 10%-11%. TAVR sales grew 11% to $1.26B. CMS draft Medicare coverage could expand TAVR access, with a final decision expected in September.
How this was made
The 30-second read
Why it matters
This is a company-specific earnings and guidance update with an additional regulatory catalyst: a CMS draft national coverage determination that could expand access to TAVR, with a final decision expected in September.
Market read
Traders can update EW’s near-term valuation using the raised FY guidance and TAVR growth outlook, while monitoring September CMS reimbursement risk as a forward demand catalyst.
What to watch
TAVR growth is attributed partly to a competitor exit and new clinical data; traders may want to watch whether growth is sustainable absent those one-time tailwinds, and how TMTT guidance narrowing affects mix and margins.
Background
Edwards is a structural heart medtech company with a major TAVR franchise and a growing transcatheter mitral and tricuspid therapies (TMTT) platform.
Ticker impact
Edwards reported Q2 revenue of $1.74B (+14%) and raised full-year guidance to 10%-11% from 9%-11%.
Bias modestly positive for the next few sessions as traders reprice FY growth and TAVR reimbursement optionality; near-term volatility likely around September CMS decision expectations.
The article discloses a fresh earnings datapoint (revenue, EPS beat) and a concrete guidance increase, plus a new regulatory timeline (final CMS decision in September) that can affect TAVR demand assumptions.
Market effects
Supports the medtech narrative that TAVR demand and reimbursement pathways remain a key driver for valve-focused peers.
Limited direct regional spillover; primarily US reimbursement-driven demand expectations.
Moderate, as the CMS coverage update is US-specific but can influence global device utilization and investor sentiment toward structural heart therapies.
Counterpoint
The CMS draft coverage update is not final, so the market may be over-discounting reimbursement upside before the September decision.
Key entities
- companyEdwards Lifesciences Corp.
Reported Q2 revenue and EPS beat, raised full-year guidance, and discussed TAVR growth drivers and CMS coverage draft expectations.
- regulatorCenters for Medicare & Medicaid Services (CMS)
Draft coverage policy could expand TAVR access; final decision expected in September.
- executiveTheodora “Doretta” Mistras
New CFO who joined in late May; first earnings under her tenure.
